Privacy PolicyTerms of Service
OslerMarket
K
Ask OslerLibraryLearn
OslerMarket

Filtered resources

Clinical library

444 resources

Explore a topic. Choose a collection. Find your next resource.

444 resources
Clear filters

Collections 3

Cardiology: ACS & Heart Failure16 resourcesHypertension9 resourcesECG & More17 resources

Collections

3 of 45
  • Cardiology: ACS & Heart Failure16 resourcesACS by Labu Albert · MANAGEMENT OF ACUTE CORONARY SYNDROME …
  • Hypertension9 resources2025 AHA/ACC Guideline for the Management of High Blood Pressure in Adults · ESC 2024 Hypertension Guidelines …
  • ECG & More17 resourcesAN INTRODUCTION TO THE ECG and arrythmias revision ECG Oct 2025 (2) · LITTLE BLACK BOOK OF ECG SECRETS …

Resources

24 shown
ACUTE CORONARY SYNDROMES coverClinical notesACUTE CORONARY SYNDROMESRobert J. DiDomenico, Paul P. Dobesh, Shannon W. Finks·Cardiology· 2023· 10 pagesThis chapter discusses acute coronary syndrome (ACS), its classification, clinical presentation, and management strategies, including the use of anticoagulants and antiplatelet agents.
INTRAVENOUS ANTIARRHYTHMIC DOSING coverClinical notesINTRAVENOUS ANTIARRHYTHMIC DOSINGJessica J. Tilton·Cardiology· 9 pagesThis chapter discusses the management and pharmacotherapy of various cardiac arrhythmias, including their clinical presentation and treatment options.
EXTENDED LOW-DOSE APIXABAN AND SUPERFICIAL VEIN THROMBOSIS coverClinical reviewsEXTENDED LOW-DOSE APIXABAN AND SUPERFICIAL VEIN THROMBOSISVanderbilt University Medical Center·Cardiology· 2026· 3 pagesThis study investigates the efficacy of extended low-dose apixaban in reducing the risk of symptomatic superficial vein thrombosis (SuVT) compared to placebo.
VITAMIN E IN THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE AND CANCER coverClinical reviewsVITAMIN E IN THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE AND CANCERnull·Cardiology· 2005· 10 pagesThis document presents findings from the Women’s Health Study, a randomized controlled trial investigating the effects of vitamin E supplementation on cardiovascular disease and cancer risks among healthy women.
ENDOCARDITIS AND BACTEREMIA coverClinical notesENDOCARDITIS AND BACTEREMIADaniel B·Cardiology· 7 pagesThis chapter provides an overview of endocarditis, including its definition, etiology, and management strategies. It discusses the clinical presentations of acute and subacute infective endocarditis and the implications of bacteremia.
AXIS DETERMINATION&R WAVE PROGRESSION coverLecture slidesAXIS DETERMINATION&R WAVE PROGRESSIONDr. Daniel Iraguha·Cardiology· 17 pagesThis presentation focuses on the determination of the ECG axis and R wave progression, essential for interpreting electrocardiograms. It covers the basics of ECG, its historical context, and the clinical significance of axis determination.
Perioperative Management of Anticoagulant and Antiplatelet Therapy coverClinical reviewsPerioperative Management of Anticoagulant and Antiplatelet TherapyJames D. Douketis, M.D., Alex C. Spyropoulos, M.D.·Cardiology· 2023· 14 pagesThis review provides an evidence-based but practical approach to managing patients on anticoagulant or antiplatelet therapy who require surgery or invasive procedures.
IMPACT OF DAPAGLIFLOZIN ON CARDIAC REMODELING IN PATIENTS WITH CHRONIC HEART FAILURE: DAPA-MODA STUDY coverClinical reviewsIMPACT OF DAPAGLIFLOZIN ON CARDIAC REMODELING IN PATIENTS WITH CHRONIC HEART FAILURE: DAPA-MODA STUDYHospital Clínico Universitario Virgen de la Arrixaca, Universidad de Murcia, Centro Nacional de Investigaciones Cardiovasculares Carlos III·Cardiology· 2023· 24 pagesThis document discusses the effects of dapagliflozin on cardiac remodeling in patients with chronic heart failure, highlighting findings from the DAPA-MODA study.
MANAGEMENT OF MITRAL STENOSIS: A SYSTEMATIC REVIEW OF CLINICAL PRACTICE GUIDELINES AND RECOMMENDATIONS coverClinical reviewsMANAGEMENT OF MITRAL STENOSIS: A SYSTEMATIC REVIEW OF CLINICAL PRACTICE GUIDELINES AND RECOMMENDATIONSKing's College Hospital, Morriston Cardiac Regional Centre, Newham University Hospital, Barts Health NHS Trust, G.d'Annunzio University, Lund University, Casa di Cura Villa Serena, NIHR Barts Biomedical Research Centre·Cardiology· 2021· 17 pagesThis document systematically reviews existing guidelines for the diagnosis and management of mitral stenosis (MS), highlighting their similarities and differences to guide clinical decision-making.
DIRECT ORAL ANTICOAGULANTS VERSUS WARFARIN ACROSS THE SPECTRUM OF KIDNEY FUNCTION: PATIENT-LEVEL NETWORK META-ANALYSES FROM COMBINE AF coverClinical reviewsDIRECT ORAL ANTICOAGULANTS VERSUS WARFARIN ACROSS THE SPECTRUM OF KIDNEY FUNCTION: PATIENT-LEVEL NETWORK META-ANALYSES FROM COMBINE AFJosephine Harrington, MD; Anthony P. Carnicelli, MD; Kaiyuan Hua, MS; Lars Wallentin, MD, PhD; Manesh R. Patel, MD; Stefan H. Hohnloser, MD; Robert P. Giugliano, MD, ScM; Keith A.A. Fox, MB, ChB; Ziad Hijazi, MD, MPH; Renato D. Lopes, MD, MHS, PhD; Sean·Cardiology· 10 pagesThis study evaluates the safety and efficacy of direct oral anticoagulants (DOACs) compared to warfarin in patients with varying levels of kidney function using data from the COMBINE AF database.
IDENTIFYING PATIENTS AT HIGH RISK OF LEFT ATRIAL APPENDAGE THROMBUS BEFORE CARDIOVERSION: THE CLOTS-AF SCORE coverClinical reviewsIDENTIFYING PATIENTS AT HIGH RISK OF LEFT ATRIAL APPENDAGE THROMBUS BEFORE CARDIOVERSION: THE CLOTS-AF SCOREJournal of the American Heart Association·Cardiology· 2023· 17 pagesThis study evaluates clinical and echocardiographic parameters to predict the risk of left atrial appendage thrombus (LAAT) in patients undergoing transesophageal echocardiography before cardioversion.
CONSENSUS STATEMENT ON THE CURRENT PHARMACOLOGICAL PREVENTION AND MANAGEMENT OF HEART FAILURE coverClinical reviewsCONSENSUS STATEMENT ON THE CURRENT PHARMACOLOGICAL PREVENTION AND MANAGEMENT OF HEART FAILUREAndrew P Sindone, Carmine De Pasquale, John Amerena, Christine Burdeniuk, Alicia Chan, Andrew Coats, David L Hare, Peter Macdonald, Aaron Sverdlov, John J Atherton·Cardiology· 2022· 6 pagesThis document presents a consensus statement focusing on the evaluation of new and established drugs for the prevention and treatment of heart failure, reflecting updates since the 2018 guidelines.
INCLISIRAN: PRESENT AND FUTURE PERSPECTIVES OF A NEW EFFECTIVE LDL CHOLESTEROL-LOWERING AGENT coverClinical reviewsINCLISIRAN: PRESENT AND FUTURE PERSPECTIVES OF A NEW EFFECTIVE LDL CHOLESTEROL-LOWERING AGENTGraecia University·Cardiology· 8 pagesThis document reviews inclisiran, a small interfering RNA that has proven its safety and efficacy in reducing LDL-cholesterol, highlighting its development, mechanism of action, and current recommendations in clinical practice.
MANAGEMENT OF VENTRICULAR ARRHYTHMIAS WORLDWIDE coverClinical reviewsMANAGEMENT OF VENTRICULAR ARRHYTHMIAS WORLDWIDEAmerican College of Cardiology Foundation·Cardiology· 2023· 14 pagesThis document compares the latest guidelines for the management of ventricular arrhythmias and the prevention of sudden cardiac death from various cardiology societies.
THE HEART FAILURE KNIGHTS coverClinical reviewsTHE HEART FAILURE KNIGHTSDepartment of Medicine, ASST Mantova, C. Poma Hospital, Italy·Cardiology· 2023· 21 pagesThis article discusses the 2021 European Society of Cardiology guidelines for the diagnosis and treatment of acute and chronic heart failure, focusing on optimal drug therapy and the introduction of new treatment options.
STATINS REVISITED: THERAPEUTIC APPLICATIONS BEYOND LIPID LOWERING? coverClinical reviewsSTATINS REVISITED: THERAPEUTIC APPLICATIONS BEYOND LIPID LOWERING?Cardiovascular Program-ICCC, IR-Hospital de la Santa Creu i Sant Pau, IIB-SantPau, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain; Cardiology Hospital Clinic, IDIBAPS, Spain·Cardiology· 2023· 3 pagesThis editorial discusses the therapeutic applications of statins beyond their lipid-lowering effects, particularly in the context of coronary artery bypass grafting (CABG). It highlights recent studies and their implications for clinical practice.
UPDATES FOR CARDIO- KIDNEY PROTECTIVE EFFECTS BY ANGIOTENSIN RECEPTOR- NEPRILYSIN INHIBITOR: REQUIREMENT FOR ADDITIONAL EVIDENCE OF KIDNEY PROTECTION coverClinical reviewsUPDATES FOR CARDIO- KIDNEY PROTECTIVE EFFECTS BY ANGIOTENSIN RECEPTOR- NEPRILYSIN INHIBITOR: REQUIREMENT FOR ADDITIONAL EVIDENCE OF KIDNEY PROTECTIONCity University·Cardiology· 14 pagesThis contemporary review discusses the potential cardio-kidney protective effects of Angiotensin Receptor-Neprilysin Inhibitor (ARNI) and the need for further evidence regarding its renoprotective capabilities.
IMPORTANT PATIENT PHENOTYPES IN PRIMARY HFPEF coverClinical reviewsIMPORTANT PATIENT PHENOTYPES IN PRIMARY HFPEFHeart Failure Association (HFA) and the European Heart Rhythm Association (EHRA) of the ESC, and the European Society of Hypertension (ESH)·Cardiology· 51 pagesThis document discusses patient phenotype profiling in heart failure with preserved ejection fraction (HFpEF) to guide therapeutic decision-making.
INITIAL STATIN DOSE AFTER MYOCARDIAL INFARCTION AND LONG-TERM CARDIOVASCULAR OUTCOMES coverClinical reviewsINITIAL STATIN DOSE AFTER MYOCARDIAL INFARCTION AND LONG-TERM CARDIOVASCULAR OUTCOMESTurku University Hospital and University of Turku·Cardiology· 2022· 9 pagesThis study investigates the impact of initial statin dosing on long-term cardiovascular outcomes in patients after myocardial infarction (MI). It highlights the suboptimal real-life dosing of statins and its implications for patient outcomes.
CURRENT AND EMERGING PHARMACOTHERAPY FOR THE MANAGEMENT OF HYPERTROPHIC CARDIOMYOPATHY coverClinical reviewsCURRENT AND EMERGING PHARMACOTHERAPY FOR THE MANAGEMENT OF HYPERTROPHIC CARDIOMYOPATHYNew York Medical College, Rowan-Virtua School of Osteopathic Medicine, MedStar Union Memorial Hospital, Tufts University School of Medicine, Westchester Medical Center, Atlantic Health·Cardiology· 2023· 13 pagesThis document provides a comprehensive review of current and emerging pharmacotherapy options for managing hypertrophic cardiomyopathy (HCM), a common genetic heart disease.
MANAGEMENT OF HYPERTENSIVE EMERGENCIES AND URGENCIES: NARRATIVE REVIEW coverClinical reviewsMANAGEMENT OF HYPERTENSIVE EMERGENCIES AND URGENCIES: NARRATIVE REVIEWMedical Units of Dumfries and Galloway Royal Infirmary, Queen Elizabeth University Hospital·Cardiology· 2021· 7 pagesThis article reviews current guidelines and recommendations for the management of hypertensive emergencies and urgencies, focusing on user-friendly strategies for general physicians.
LIPID MEASUREMENTS IN THE MANAGEMENT OF CARDIOVASCULAR DISEASES: PRACTICAL RECOMMENDATIONS coverClinical reviewsLIPID MEASUREMENTS IN THE MANAGEMENT OF CARDIOVASCULAR DISEASES: PRACTICAL RECOMMENDATIONSEmory University School of Medicine; Atlanta Veterans Affairs Medical Center; Johns Hopkins University School of Medicine; St. David’s Medical Center; University of Chicago School of Medicine; Centers for Disease Control and Prevention; Rigshospitalet,·Cardiology· 20 pagesThis document provides practical recommendations for lipid measurements crucial in managing patients at risk for atherosclerotic cardiovascular diseases, including coronary heart disease and stroke.
Beta-Blocker Use and Heart Failure Outcomes in Mildly Reduced and Preserved Ejection Fraction coverClinical reviewsBeta-Blocker Use and Heart Failure Outcomes in Mildly Reduced and Preserved Ejection FractionSuzanne V. Arnold, Daniel N. Silverman, Kensey Gosch, Michael E. Nassif, Margaret Infeld, Sheldon Litwin, Markus Meyer, Timothy J. Fendler·Cardiology· 8 pagesThis study examines the association of beta-blocker use with heart failure hospitalization and death in patients with mildly reduced ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF). It found that beta-blockers were associated with decreased risk in HFmrEF but a lack of survival benefit and higher risk of hospitalization in HFpEF.
NYHA CLASSIFICATION FOR DECISION-MAKING IN HEART FAILURE: TIME TO REASSESS? coverClinical reviewsNYHA CLASSIFICATION FOR DECISION-MAKING IN HEART FAILURE: TIME TO REASSESS?Post-Graduate Program in Cardiology and Cardiovascular Sciences, Medical School, Universidade Federal do Rio Grande do Sul; Cardiovascular Division, Hospital de Clínicas de Porto Alegre; Cardiovascular Division, Brigham and Women's Hospital·Cardiology· 4 pagesThis document discusses the New York Heart Association (NYHA) classification system for categorizing patients with heart failure based on symptoms and physical activity limitations. It highlights the system's historical significance and its implications for clinical trials and treatment decisions.
PreviousPage 13 of 19Next

© 2026 Osler Market

Library·Ask Osler·Learn·Terms·Privacy·Support·WhatsApp Channel

For learning purposes. Always consult clinical guidelines.

Ask OslerLibraryLearn
HomeAskLibraryLearnAccount